Join Clinical Trials in Kansas for Allergies

All Categories Medical Conditions » Allergies » Kansas

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

Condition: Asthma
Interventions: Drug: MEMP1972A; Drug: MEMP1972A; Drug: MEMP1972A; Drug: placebo
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012
A Dose-ranging Study of Fluticasone Furoate (FF)

Condition: Asthma
Interventions: Drug: Fluticasone Furoate; Drug: Fluticasone Propionate; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified March 2012
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

Condition: Asthma
Interventions: Drug: Fluticasone propionate 100mcg; Drug: Placebo; Drug: Vilanterol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012
A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Matching Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

Condition: ACE Inhibitor Induced Angioedema
Interventions: Drug: ecallantide; Drug: ecallantide; Drug: ecallantide; Drug: placebo
Sponsors: Dyax Corp.; Dyax Corp.
Recruiting - verified April 2012
Efficacy, Safety, and Tolerability of SAR231893(REGN668) in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Condition: Asthma
Interventions: Biological: SAR231893 (REGN668); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified April 2012
To Evaluate the Use of ASTHMA IQ in a Primary Care Setting

Condition: Asthma
Intervention:
Sponsors: American Academy of Family Physicians; American Academy of Family Physicians; American Academy of Allergy, Asthma, and Immunology
Recruiting - verified January 2012
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

Condition: Hereditary Angioedema
Intervention: Drug: ecallantide
Sponsors: Dyax Corp.; Dyax Corp.
Recruiting - verified April 2012
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

Condition: Atopic Dermatitis
Intervention:
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012